Obermatt

Procter & Gamble

NYQ:PG · US7427181091
Household ProductsXX-Large

360

52
EV / EBIT26
Price / Owner Earnings39
Owner Earnings Yield49
Dividend Yield100
Price/Sales52
EV / Gross Profit18
Price/Book19
Return on Capital76
Cash Return on Capital73
Return on Equity76
EBIT Margin95
Gross Profitability29
Cash Conversion34
Accruals39
Owner Earnings Margin83
Sales growth31
Profit Growth100
Long-Term EPS Growth35
Owner Earnings Growth40
Reinvestment46
Price momentum39
Debt load37
Refinancing34
Debt Payback37
Liquidity97
Analyst ratings23
Opinion Changes50
Price Target Upside42
Market mood71
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Procter & Gamble clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHousehold Products
SizeXX-Large
TypePublic Company
ExchangeNYSE
Founded1905
Employees72,836
Websiteus.pg.com
ISINUS7427181091
Last UpdateApr 2, 2026
Themes
Fast-Moving Consumer GoodsLifestyleBeautyBrand MarketingConsumerConsumer GoodsCosmeticsNutritionPetPharmaceutical

Description

The Procter & Gamble Company (P&G) operates as a multinational consumer goods company. The company focuses on providing trusted, branded products of superior quality, performance and value to improve the lives of consumers around the world. The comp…

Analysis

Middle-of-the-road

The Procter & Gamble Company sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 22.5×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 8% a year, against analyst forecasts of 5%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
81
2023202420252026

All-time high

96

Jul 2023

All-time low

37

Jan 2026

Average rank

68

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
52
20
24
22
Price/Earnings
22
41
39
41
Price/Book
19
17
16
20
Dividend Yield
100
86
82
84
Value (overall)
76
62
49
45

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Procter & Gamble with its peers
Procter & Gamble Health
NSI:PGHL
72
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Merck (USA)
NYQ:MRK
35
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Amphastar Pharmaceuticals
NSQ:AMPH
63
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cumberland Pharmaceuticals
NSQ:CPIX
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
ANI Pharma
NMQ:ANIP
98
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →